Roche Holding AG (ROG.SW)
| Previous close | 220.00 |
| Open | 219.30 |
| Bid | 222.00 x 0 |
| Ask | 223.90 x 0 |
| Day's range | 218.50 - 222.10 |
| 52-week range | 217.00 - 293.55 |
| Volume | |
| Avg. volume | 1,418,216 |
| Market cap | 178.877B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 15.53 |
| EPS (TTM) | 14.30 |
| Earnings date | 01 Feb 2024 |
| Forward dividend & yield | 9.60 (4.36%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 277.06 |
ZacksRoche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
ZacksPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
Globe NewswireFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF
